Ten THC Meta-Analysis Studies Contributed Cardiovascular Outcomes They Were Not Primarily Designed to Test
The cardiovascular review notes that ten included studies were not primarily designed to assess THC’s cardiovascular effects. Their secondary measurements contributed useful data while limiting the strength of a dedicated cardiovascular inference.
Relevant data can arise outside the main study question
A trial examining another outcome may still collect heart rate or blood pressure. Such observations can inform a synthesis when they meet its eligibility criteria. The authors nevertheless describe these secondary haemodynamic findings as hypothesis-generating, recognizing that the original protocols were not necessarily optimized for that purpose.
Measurement design can limit interpretation
Assessment frequency, observation duration and sample size may have been chosen for another endpoint. A study could therefore capture a cardiovascular change without characterizing its full course or providing precise estimates for that variable. The review does not establish that every secondary outcome was unreliable; it identifies a limitation on what the combined evidence was designed to answer.
Report the source of the estimate accurately
A meta-analysis containing secondary measurements should not be described as if every component were a dedicated cardiovascular trial. Its value lies partly in identifying signals and gaps for better targeted research. This distinction matters when a pooled physiological result is invoked as a clinical prediction or a statement of cardiovascular safety. The presence of relevant measurements does not eliminate the need to examine the original study’s purpose and protocol.
Related analysis: the study’s broader findings and limitations.
